Erics Langer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

12/03/21 Pharmaceutical Online Newsletter

Cell & Gene Therapy Bioprocessing: Demand For Better Process Control, Expertise & CMOs By Ronald A. Rader and Eric S. Langer, BioPlan Associates, Inc. Manufacturing capacity for both cellular therapies and gene therapy viral vectors remains in short supply.  From our research, including interviews with developers, there is a current and worsening capacity crunch. BioPlan Associates, Inc. annually surveys biopharmaceutical manufacturing professionals and publishes data on capacity and other industry concerns. 1 The survey, now in its 18 th year, includes 147 end users’ responses and also pr...

Looking Back And Moving Forward In The Fight Against SARS-CoV-2 By Eric S. Langer, Managing Partner, BioPlan Associates, Inc., Christopher Murphy, Vice President/General Manager, Viral Vector/Pharma Services, Thermo Fisher Scientific, Brandon Pence, Vice President/General Manager, Purification and Pharma Analytics, Thermo Fisher Scientific, Chris Williams, Vice President/General Manager, Single-Use Technologies, Thermo Fisher Scientific, Kate Torchilin, Vice President/General Manager, Cell Culture and Cell Therapy, Thermo Fisher Scientific The unprecedented global crisis brought on by SARS-Co...

Bioprocessing Year In Review: 11 Key Trends Accelerated By COVID-19 By Ronald A. Rader and Eric S. Langer, BioPlan Associates, Inc. Over the past 17 years we have identified a number of trends that are impacting bioprocessing and biopharmaceuticals manufacturing, the majority of which have promised positive outcomes.  With the COVID-19 crisis, many of these ongoing trends have been accelerated. Although it seems we may now be seeing the light at the end of the COVID tunnel, some of the effects of the pandemic on bioprocessing and vaccines manufacturing may result in permanent changes. Major ...